The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 18, 2006
Filed:
Jul. 31, 2002
Sally J. Denardo, El Macerco, CA (US);
Patricia A. Burke, Sacramento, CA (US);
Gerald L. Denardo, El Macerco, CA (US);
Simon Goodman, Darmstadt, DE;
Kerstin Matzku, Legal Representative, Zwingenberg, DE;
Sally J. DeNardo, El Macerco, CA (US);
Patricia A. Burke, Sacramento, CA (US);
Gerald L. DeNardo, El Macerco, CA (US);
Simon Goodman, Darmstadt, DE;
Kerstin Matzku, legal representative, Zwingenberg, DE;
The Regents of the University of California, Oakland, CA (US);
Merck Patent GmbH, Darmstadt, DE;
Abstract
A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.